-
Something wrong with this record ?
Belinostat, at Its Clinically Relevant Concentrations, Inhibits Rifampicin-Induced CYP3A4 and MDR1 Gene Expression
KL. Abbott, CS. Chaudhury, A. Chandran, S. Vishveshwara, Z. Dvorak, E. Jiskrova, K. Poulikova, B. Vyhlidalova, S. Mani, SR. Pondugula,
Language English Country United States
Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
Grant support
P30 CA013330
NCI NIH HHS - United States
R01 CA161879
NCI NIH HHS - United States
R01 CA222469
NCI NIH HHS - United States
NLK
Open Access Digital Library
from 1965-07-01
Open Access Digital Library
from 1997-01-01
ROAD: Directory of Open Access Scholarly Resources
- MeSH
- Cytochrome P-450 CYP3A metabolism MeSH
- Adult MeSH
- Gene Expression drug effects MeSH
- Hepatocytes drug effects metabolism MeSH
- Irinotecan pharmacology MeSH
- Hydroxamic Acids pharmacology MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Cell Line, Tumor MeSH
- ATP Binding Cassette Transporter, Subfamily B metabolism MeSH
- Pregnane X Receptor metabolism MeSH
- Rifampin pharmacology MeSH
- Molecular Docking Simulation methods MeSH
- Receptors, Steroid metabolism MeSH
- Sulfonamides pharmacology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Research Support, N.I.H., Extramural MeSH
Activation of human pregnane X receptor (hPXR) has been associated with induction of chemoresistance. It has been proposed that such chemoresistance via cytochrome P450/drug transporters can be reversed with the use of antagonists that specifically abrogate agonist-mediated hPXR activation. Unfortunately, proposed antagonists lack the specificity and appropriate pharmacological characteristics that allow these features to be active in the clinic. We propose that, ideally, an hPXR antagonist would be a cancer drug itself that is part of a "cancer drug cocktail" and effective as an hPXR antagonist at therapeutic concentrations. Belinostat (BEL), a histone deacetylase inhibitor approved for the treatment of relapsed/refractory peripheral T-cell lymphoma, and often used in combination with chemotherapy, is an attractive candidate based on its hPXR ligand-like features. We sought to determine whether these features of BEL might allow it to behave as an antagonist in combination chemotherapy regimens that include hPXR activators. BEL represses agonist-activated hPXR target gene expression at its therapeutic concentrations in human primary hepatocytes and LS174T human colon cancer cells. BEL repressed rifampicin-induced gene expression of CYP3A4 and multidrug resistance protein 1, as well as their respective protein activities. BEL decreased rifampicin-induced resistance to SN-38, the active metabolite of irinotecan, in LS174T cells. This finding indicates that BEL could suppress hPXR agonist-induced chemoresistance. BEL attenuated the agonist-induced steroid receptor coactivator-1 interaction with hPXR, and, together with molecular docking studies, the study suggests that BEL directly interacts with multiple sites on hPXR. Taken together, our results suggest that BEL, at its clinically relevant therapeutic concentration, can antagonize hPXR agonist-induced gene expression and chemoresistance.
Albert Einstein Cancer Center Albert Einstein College of Medicine New York New York
Department of Anatomy Physiology and Pharmacology Auburn University Auburn Alabama
Molecular Biophysics Unit Indian Institute of Science Bangalore India
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19027929
- 003
- CZ-PrNML
- 005
- 20190823124812.0
- 007
- ta
- 008
- 190813s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1124/mol.118.114587 $2 doi
- 035 __
- $a (PubMed)30622215
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Abbott, Kodye L $u Department of Anatomy, Physiology and Pharmacology (K.L.A., C.S.C., S.R.P.) and Auburn University Research Initiative in Cancer (K.L.A., C.S.C., S.R.P.), Auburn University, Auburn, Alabama; Molecular Biophysics Unit, Indian Institute of Science, Bangalore, India (A.C., S.V.); Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacky University, Olomouc, Czech Republic (Z.D., E.J., K.P., B.V.); and Albert Einstein Cancer Center, Albert Einstein College of Medicine, New York, New York (S.M.).
- 245 10
- $a Belinostat, at Its Clinically Relevant Concentrations, Inhibits Rifampicin-Induced CYP3A4 and MDR1 Gene Expression / $c KL. Abbott, CS. Chaudhury, A. Chandran, S. Vishveshwara, Z. Dvorak, E. Jiskrova, K. Poulikova, B. Vyhlidalova, S. Mani, SR. Pondugula,
- 520 9_
- $a Activation of human pregnane X receptor (hPXR) has been associated with induction of chemoresistance. It has been proposed that such chemoresistance via cytochrome P450/drug transporters can be reversed with the use of antagonists that specifically abrogate agonist-mediated hPXR activation. Unfortunately, proposed antagonists lack the specificity and appropriate pharmacological characteristics that allow these features to be active in the clinic. We propose that, ideally, an hPXR antagonist would be a cancer drug itself that is part of a "cancer drug cocktail" and effective as an hPXR antagonist at therapeutic concentrations. Belinostat (BEL), a histone deacetylase inhibitor approved for the treatment of relapsed/refractory peripheral T-cell lymphoma, and often used in combination with chemotherapy, is an attractive candidate based on its hPXR ligand-like features. We sought to determine whether these features of BEL might allow it to behave as an antagonist in combination chemotherapy regimens that include hPXR activators. BEL represses agonist-activated hPXR target gene expression at its therapeutic concentrations in human primary hepatocytes and LS174T human colon cancer cells. BEL repressed rifampicin-induced gene expression of CYP3A4 and multidrug resistance protein 1, as well as their respective protein activities. BEL decreased rifampicin-induced resistance to SN-38, the active metabolite of irinotecan, in LS174T cells. This finding indicates that BEL could suppress hPXR agonist-induced chemoresistance. BEL attenuated the agonist-induced steroid receptor coactivator-1 interaction with hPXR, and, together with molecular docking studies, the study suggests that BEL directly interacts with multiple sites on hPXR. Taken together, our results suggest that BEL, at its clinically relevant therapeutic concentration, can antagonize hPXR agonist-induced gene expression and chemoresistance.
- 650 _2
- $a P-glykoproteiny $x metabolismus $7 D018435
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a cytochrom P-450 CYP3A $x metabolismus $7 D051544
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a exprese genu $x účinky léků $7 D015870
- 650 _2
- $a hepatocyty $x účinky léků $x metabolismus $7 D022781
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kyseliny hydroxamové $x farmakologie $7 D006877
- 650 _2
- $a irinotekan $x farmakologie $7 D000077146
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a simulace molekulového dockingu $x metody $7 D062105
- 650 _2
- $a pregnanový X receptor $x metabolismus $7 D000077297
- 650 _2
- $a steroidní receptory $x metabolismus $7 D011987
- 650 _2
- $a rifampin $x farmakologie $7 D012293
- 650 _2
- $a sulfonamidy $x farmakologie $7 D013449
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Chaudhury, Chloe S $u Department of Anatomy, Physiology and Pharmacology (K.L.A., C.S.C., S.R.P.) and Auburn University Research Initiative in Cancer (K.L.A., C.S.C., S.R.P.), Auburn University, Auburn, Alabama; Molecular Biophysics Unit, Indian Institute of Science, Bangalore, India (A.C., S.V.); Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacky University, Olomouc, Czech Republic (Z.D., E.J., K.P., B.V.); and Albert Einstein Cancer Center, Albert Einstein College of Medicine, New York, New York (S.M.).
- 700 1_
- $a Chandran, Aneesh $u Department of Anatomy, Physiology and Pharmacology (K.L.A., C.S.C., S.R.P.) and Auburn University Research Initiative in Cancer (K.L.A., C.S.C., S.R.P.), Auburn University, Auburn, Alabama; Molecular Biophysics Unit, Indian Institute of Science, Bangalore, India (A.C., S.V.); Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacky University, Olomouc, Czech Republic (Z.D., E.J., K.P., B.V.); and Albert Einstein Cancer Center, Albert Einstein College of Medicine, New York, New York (S.M.).
- 700 1_
- $a Vishveshwara, Saraswathi $u Department of Anatomy, Physiology and Pharmacology (K.L.A., C.S.C., S.R.P.) and Auburn University Research Initiative in Cancer (K.L.A., C.S.C., S.R.P.), Auburn University, Auburn, Alabama; Molecular Biophysics Unit, Indian Institute of Science, Bangalore, India (A.C., S.V.); Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacky University, Olomouc, Czech Republic (Z.D., E.J., K.P., B.V.); and Albert Einstein Cancer Center, Albert Einstein College of Medicine, New York, New York (S.M.).
- 700 1_
- $a Dvorak, Zdenek $u Department of Anatomy, Physiology and Pharmacology (K.L.A., C.S.C., S.R.P.) and Auburn University Research Initiative in Cancer (K.L.A., C.S.C., S.R.P.), Auburn University, Auburn, Alabama; Molecular Biophysics Unit, Indian Institute of Science, Bangalore, India (A.C., S.V.); Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacky University, Olomouc, Czech Republic (Z.D., E.J., K.P., B.V.); and Albert Einstein Cancer Center, Albert Einstein College of Medicine, New York, New York (S.M.).
- 700 1_
- $a Jiskrova, Eva $u Department of Anatomy, Physiology and Pharmacology (K.L.A., C.S.C., S.R.P.) and Auburn University Research Initiative in Cancer (K.L.A., C.S.C., S.R.P.), Auburn University, Auburn, Alabama; Molecular Biophysics Unit, Indian Institute of Science, Bangalore, India (A.C., S.V.); Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacky University, Olomouc, Czech Republic (Z.D., E.J., K.P., B.V.); and Albert Einstein Cancer Center, Albert Einstein College of Medicine, New York, New York (S.M.).
- 700 1_
- $a Poulikova, Karolina $u Department of Anatomy, Physiology and Pharmacology (K.L.A., C.S.C., S.R.P.) and Auburn University Research Initiative in Cancer (K.L.A., C.S.C., S.R.P.), Auburn University, Auburn, Alabama; Molecular Biophysics Unit, Indian Institute of Science, Bangalore, India (A.C., S.V.); Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacky University, Olomouc, Czech Republic (Z.D., E.J., K.P., B.V.); and Albert Einstein Cancer Center, Albert Einstein College of Medicine, New York, New York (S.M.).
- 700 1_
- $a Vyhlidalova, Barbora $u Department of Anatomy, Physiology and Pharmacology (K.L.A., C.S.C., S.R.P.) and Auburn University Research Initiative in Cancer (K.L.A., C.S.C., S.R.P.), Auburn University, Auburn, Alabama; Molecular Biophysics Unit, Indian Institute of Science, Bangalore, India (A.C., S.V.); Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacky University, Olomouc, Czech Republic (Z.D., E.J., K.P., B.V.); and Albert Einstein Cancer Center, Albert Einstein College of Medicine, New York, New York (S.M.).
- 700 1_
- $a Mani, Sridhar $u Department of Anatomy, Physiology and Pharmacology (K.L.A., C.S.C., S.R.P.) and Auburn University Research Initiative in Cancer (K.L.A., C.S.C., S.R.P.), Auburn University, Auburn, Alabama; Molecular Biophysics Unit, Indian Institute of Science, Bangalore, India (A.C., S.V.); Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacky University, Olomouc, Czech Republic (Z.D., E.J., K.P., B.V.); and Albert Einstein Cancer Center, Albert Einstein College of Medicine, New York, New York (S.M.) srp0010@auburn.edu sridhar.mani@einstein.yu.edu.
- 700 1_
- $a Pondugula, Satyanarayana R $u Department of Anatomy, Physiology and Pharmacology (K.L.A., C.S.C., S.R.P.) and Auburn University Research Initiative in Cancer (K.L.A., C.S.C., S.R.P.), Auburn University, Auburn, Alabama; Molecular Biophysics Unit, Indian Institute of Science, Bangalore, India (A.C., S.V.); Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacky University, Olomouc, Czech Republic (Z.D., E.J., K.P., B.V.); and Albert Einstein Cancer Center, Albert Einstein College of Medicine, New York, New York (S.M.) srp0010@auburn.edu sridhar.mani@einstein.yu.edu.
- 773 0_
- $w MED00003399 $t Molecular pharmacology $x 1521-0111 $g Roč. 95, č. 3 (2019), s. 324-334
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30622215 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20190823125026 $b ABA008
- 999 __
- $a ok $b bmc $g 1433078 $s 1066389
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 95 $c 3 $d 324-334 $e 20190108 $i 1521-0111 $m Molecular pharmacology $n Mol Pharmacol $x MED00003399
- GRA __
- $a P30 CA013330 $p NCI NIH HHS $2 United States
- GRA __
- $a R01 CA161879 $p NCI NIH HHS $2 United States
- GRA __
- $a R01 CA222469 $p NCI NIH HHS $2 United States
- LZP __
- $a Pubmed-20190813